![ORCID Icon]({"type":"image","src":"/templates/jsp/_style2/_tandf/images/orcid.svg"} "ORCID Icon"){kind=small}
http://orcid.org/0000-0002-7531-9732
![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
![Molecular Psychology F1000 Promotion]({"type":"image" , "src" : "/sda/111182/JournalAd-Announce-Molecular-Psychology-F1000-Submission-RA.jpg"})
![Call for Papers.]({"type":"image" , "src" : "/sda/111134/JournalAdOASubmissionCAIC.jpg"})
Abstract
Objectives: Although there is consistent evidence that electroconvulsive therapy (ECT) is safe and well tolerated by the majority of patients, some authors still accuse ECT to inevitably cause brain damage and permanent memory loss, assertions that may increase patients’ worries about a useful treatment. Recently, the measurement of neurofilament light chain (NFL) in peripheral blood was technically implemented, permitting longitudinal analysis of this biomarker for axonal damage. NFL is part of the axonal cytoskeleton and is released into the CSF and peripheral blood in the context of neuronal damage.
Methods: In our study, blood from 15 patients with major depressive disorder receiving ECT was collected before the first ECT as well as 24 h and seven days after the last ECT, respectively. NFL concentrations were analysed using the ultrasensitive single molecule array (Simoa) technology.
Results: NFL concentrations did not differ between patients and healthy controls, and there was no significant change in NFL levels in the course of ECT. On the contrary, we even found a slight decrease in absolute NFL concentrations.
Conclusions: Our study confirms the safety of ECT by using a most sensitive method for the detection of NFL in peripheral blood as a biomarker of neuronal damage.
Acknowledgements
None.
Ethical approval
This study has been approved by the local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Statement of interest
Prof Jens Wiltfang is member of the following advisory boards: Abbott, Boehringer Ingelheim, Immungenetics, Lilly, MSD Sharp & Dohme, Roche Pharma and gave honoraria lectures for:
AGNP, Actelion, Amgen, CSF-Society, Helios Klinikum Wuppertal, Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, Vitos Kurhessen-Bad Emstal.
Patents: PCT/EP 2011 001724; PCT/EP 2015 052945